Leen Heyens

Dr. Leen Heyens

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DBDana Busschots
Dana Busschots
CKCécile Kremer
Cécile Kremer
RBRob Bielen
Rob Bielen
ÖKÖzgür M. Koc
Özgür M. Koc
LHLeen Heyens
Leen Heyens
GRGeert Robaeys
Geert Robaeys
Background: Prevalence data on viral hepatitis B (HBV), hepatitis C (HCV), and HIV infection in prison are often scarce or outdated. There is currently no systematic screening for these blood-borne viral infections (BBV) in Belgian prisons. There is an urgency to assess the prevalence of these BBV to inform policymakers and public healthcare. Methods: This was a multicentre, interventional study to assess the prevalence of BBV using opt-in screening in prisons across Belgium, April 2019 – March 2020. Prisoners were tested using a finger prick and BBV risk factors were assessed using a questionnaire. A generalized linear mixed model was used to investigate the association between the various risk factors and HCV. Results: In total, 886 prisoners from 11 Belgian prisons were screened. Study uptake ranged from 16.9 to 35.4% in long-term facilities. The prevalence of HCV antibodies (Ab), hepatitis B surface antigen (Ag) and HIV Ab/Ag was 5.0% (44/886), 0.8% (7/886), and 0.2% (2/886). The adjusted odds for HCV Ab were highest in prisoners who ever injected (p < 0.001; AOR 24.6 CI 95% (5.5–215.2). The prevalence of detectable HCV RNA in the total cohort was 2.1% (19/886). Thirteen (68.4%) prisoners were redirected for follow-up of their HCV infection. Conclusions: Opt-in testing for viral hepatitis B, C and HIV was relatively well-accepted in prisons. Compared with the general population, prisoners have a higher prevalence of infection with BBV, especially for HCV. Systematic screening for these BBV should be recommended in all prisons, preferably using opt-out to optimize screening uptake. Trial registration: Retrospectively registered at clinical trials NCT04366492 April 29, 2020.

24 December 2025 in Annals of Hepatology
Verified
Journal Article
Open access
LHLeen Heyens
Leen Heyens
DMDemi P.A. van Malde
Demi P.A. van Malde
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
MSMathieu Struyve
Mathieu Struyve
IAI.N. Akpinar
I.N. Akpinar
The screening accuracy of non-invasive fibrosis tests like FIB-4 in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Using standard cut-offs, this study evaluated FIB-4's agreement with vibration-controlled transient elastography (VCTE) and identified and validated new thresholds. A prospective cohort study (2019-2024) in Belgian and Dutch primary care used VCTE by FibroScan® (Echosens, France) as a proxy for the fibrosis stage. The FIB-4 index was derived from electronic patient data and study blood samples. Agreement between VCTE and FIB-4 was analysed using weighted Cohen's kappa. New fibrosis cut-offs (≥F2; ≥8 kPa) for ≤65 and >65 years were determined via Youden's Index and validated in a Turkish primary care cohort and a Belgian secondary care T2DM cohort. Among 563 participants (median age 62 years, 47.1 % male, 14.2 % with T2DM, median BMI 28.2 kg/m²), FIB-4 showed poor agreement with VCTE (κ = 0.138, 95 % CI: 0.069-0.207). Suggested new cut-offs of 1.29 (≤65 years) and 1.72 (>65 years) were proposed. The 1.29 cut-off performed similarly to the existing 1.3 in validation cohorts. In the Türkiye and T2DM cohorts, the 1.72 cut-off improved sensitivity over 2.0 but had lower specificity. The FIB-4 index showed poor agreement with VCTE and low sensitivity, making it an unreliable standalone diagnostic tool for liver fibrosis in people with MASLD in both primary and secondary care. Alternative non-invasive tests or improved cut-off values are needed for accurate fibrosis detection in clinical practice.

17 March 2026 in Liver International
Verified
Journal Article
Open access
PDF file
LHLeen Heyens
Leen Heyens
CSC. Van Steenkiste
C. Van Steenkiste
MSM. Struyve
M. Struyve
SFS. M. Francque
S. M. Francque
GKG. H. Koek
G. H. Koek
TGthe MASLD Research Group
the MASLD Research Group
Background: Data on quality of life in a low fibrosis prevalence metabolic dysfunction‐associated steatotic liver disease (MASLD) cohort are scarce, as previous research has focused on advanced fibrosis and cirrhosis. This study examined the association between steatosis and general and mental health, as well as productivity in patients in primary care and a diabetes population. Methods: Three cohort studies were conducted in Belgian and Dutch primary care and a Belgian hospital. Liver stiffness (> 12 kPa) and steatosis (> 275 dB/m) were measured using vibration‐controlled transient elastography and controlled attenuation parameter (CAP). Participants completed questionnaires measuring anxiety (GAD‐7), depression (PHQ‐9), work productivity (WPAI‐SHP), and general health (SF‐36), and data were analysed with Spearman correlation. Results: Of 311 participants, 142 (45.7%) and 15 (4.7%) had steatosis and fibrosis. Individuals with steatosis had a higher BMI (30.5 kg/m 2 vs. 25.5 kg/m 2 , p < 0.001), increased liver stiffness (5.7 kPa vs. 4.6 kPa, p < 0.001), lower general health scores (SF‐36, p < 0.001) and physical functioning (SF‐36, p = 0.024) compared to those without. No significant differences were found for depression ( p = 0.955) or anxiety ( p = 0.557). Absenteeism was more prevalent in the steatosis group ( p = 0.016), though the reasons for absenteeism were mostly unrelated to steatosis. Higher CAP values were negatively correlated with physical functioning ( r = −0.193, p < 0.001), energy/fatigue ( r = −0.112, p = 0.049), and general health ( r = −0.235, p < 0.001) in the total cohort. Conclusion: Steatosis does not appear to affect anxiety or depression, but does negatively affect general health perception and physical activity. Further investigation is needed to determine whether a potential relationship between work productivity and steatosis exists.

19 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LHLeen Heyens
Leen Heyens
FIFrancesco Don Innocenti
Francesco Don Innocenti
CSChristophe Van Steenkiste
Christophe Van Steenkiste
MSMathieu Struyve
Mathieu Struyve
SFSven M Francque
Sven M Francque
OGon behalf of the MASLD Research Group
on behalf of the MASLD Research Group
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely intertwined with glucose metabolism status (GMS). Bi-national comparative epidemiological data are lacking; therefore, this study aimed to provide new insights into MASLD and fibrosis prevalence and risk factors in Belgium, while comparing data from The Netherlands to uncover cross-country differences. Materials and Methods: A prospective cohort study (2019–2024) in Belgian primary and secondary care was compared with the Dutch Maastricht Study. Liver fat was measured using CAP (FibroScan®), and anthropometric, clinical, and biochemical data were collected. Associations with CAP were analysed using multivariable linear regression, including sex, age, BMI, MetS, high SBP, CVD history, and country. Results: A total of 2436 individuals (Belgium and The Netherlands) were screened, of which 1928 were eligible: MASLD with normal GMS (38.3%), prediabetes (19.2%), and type 2 diabetes mellitus (T2DM; 42.5%). Belgian participants with T2DM had higher BMI and prevalence of MASLD. CAP values were significantly associated with female sex (−7.5 dB/m, 95%CI (−11.834; −3.056), p < 0.001), BMI (5.184 dB/m, 95%CI (4.627; 5.741), p < 0.001), and MetS (13.7 dB/m, 95%CI (8.456; 18.994), p < 0.001). Country-specific interactions showed differing effects of high SBP and CVD on CAP between Belgium and The Netherlands, with only the inverse association of CVD history (−10.756, 95%CI (−17.485; −4.027), p = 0.002) with CAP in The Netherlands being significant. Conclusions: MASLD and fibrosis are common in people with prediabetes and T2DM, underscoring the need for early detection and management. Obesity and metabolic risk were key factors, while a history of CVD appeared protective in the Dutch cohort but not in the Belgian one.

29 November 2024 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
LHLeen Heyens
Leen Heyens
HKHanna Kenjic
Hanna Kenjic
PDPieter Dagnelie
Pieter Dagnelie
CSCasper G. Schalkwijk
Casper G. Schalkwijk
CSCoen Stehouwer
Coen Stehouwer
GKGer H. Koek
Ger H. Koek
Objective Glucose metabolism status (GMS) is linked to non-alcoholic fatty liver disease (NAFLD). Higher levels of advanced glycation end products (AGEs) are observed in people with type 2 diabetes mellitus (T2DM) and NAFLD. We examined the association between GMS, non-invasive tests and AGEs, with liver steatosis and fibrosis. Methods Data from The Maastricht Study, a population-based cohort, were analysed. Participants with alcohol overconsumption or missing data were excluded. GMS was determined via an oral glucose tolerance test. AGEs, measured by skin autofluorescence (SAF), were assessed using an AGE Reader. Associations of GMS and SAF with the fibrosis-4 score (FIB-4), Forns index (FI) and fatty liver index (FLI) were investigated using multivariable linear regression, adjusted for sociodemographic, lifestyle and clinical variables. Results 1955 participants (56.6%) were analysed: 598 (30.6%) had T2DM, 264 (13.5%) had pre-diabetes and 1069 (54.7%) had normal glucose metabolism. Pre-diabetes was significantly associated with FLI (standardised regression coefficient (Stβ) 0.396, 95% CI 0.323 to 0.471) and FI (Stβ 0.145, 95% CI 0.059 to 0.232) but not FIB-4. T2DM was significantly associated with FLI (Stβ 0.623, 95% CI 0.552 to 0.694) and FI (Stβ 0.307, 95% CI 0.226 to 0.388) but not FIB-4. SAF was significantly associated with FLI (Stβ 0.083, 95% CI 0.036 to 0.129), FI (Stβ 0.106, 95% CI 0.069 to 0.143) and FIB-4 (Stβ 0.087, 95% CI 0.037 to 0.137). Conclusion The study showed that adverse GMS and higher glycaemia are positively associated with steatosis. FI, but not FIB-4, was related to adverse GMS concerning fibrosis. This study is the first to demonstrate that SAF is positively associated with steatosis and fibrosis.

17 April 2026 in Diseases
Verified
Journal Article
Open access
PDF file
IGIrini Gergianaki
Irini Gergianaki
FAFoteini Anastasiou
Foteini Anastasiou
SPSophia Papadakis
Sophia Papadakis
MAMarilena Anastasaki
Marilena Anastasaki
Manolis LinardakisManolis Linardakis
Manolis Linardakis
Christos LionisChristos Lionis
Christos Lionis
Objectives: The objective of this study was to investigate metabolic dysfunction-associated steatotic liver disease (MASLD)-related awareness, health literacy (HL), and illness perception among patients at risk of MASLD in European primary care settings. Methods: Participants aged ≥50 years with either obesity, metabolic syndrome (MetS), or type 2 diabetes mellitus (T2DM), and attending general practices (GPs) in Greece, Spain, or The Netherlands were included in the study. The participants completed surveys to collect data on their socio-demographic characteristics and health habits, including the European Health Literacy Survey (HLS-E-Q16), the Brief Illness Perception Questionnaire [B-IPQ], and the Public Awareness of NAFLD Questionnaire. Results: Overall, 234 patients participated in the study (mean age: 66.5 ± 9.5 years; 45.7% were male). Among the participants, 64.5%, 66.2%, and 59.8% had a diagnosis of diabetes, obesity, and MetS, respectively. Almost one-third (27.9%) had never heard about MASLD or discussed MASLD with their GP. Twelve percent (12.1%) had never heard about cirrhosis, and 20.5% were unaware that liver disorders may cause serious health problems. Overall, 43.6% of the patients had a sufficient level of HL (score >13) with a mean score of 11.5 ± 3.3. Illness perception (B-IPQ score) was low at 41.6 ± 11.6. Significantly higher B-IPQ scores were documented for female compared to male respondents (43.1 vs. 39.8; p < 0.01). Multivariate analysis found that knowledge about MASLD was associated with higher HLS-E-Q16 (p = 0.017) and B-IPQ (p = 0.028) scores. Conclusions: Despite being at risk, a significant proportion of the study participants were unaware of MASLD, its risk factors, and their personal susceptibility. This study underscores the importance of enhancing patient HL and promoting prevention and risk reduction, particularly among high-risk patient populations.